<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The <z:chebi fb="0" ids="37550">sphingosine-1-phosphate</z:chebi> (S1P) receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> fingolimod (FTY720), that has shown efficacy in advanced multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> clinical trials, decreases reperfusion injury in heart, liver, and kidney </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore tested the therapeutic effects of fingolimod in several <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To assess the translational significance of these findings, we asked whether fingolimod improved long-term behavioral outcomes, whether delayed treatment was still effective, and whether neuroprotection can be obtained in a second species </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and cell-culture models of neurotoxicity and <z:mp ids='MP_0001845'>inflammation</z:mp> to examine the therapeutic potential and mechanisms of neuroprotection by fingolimod </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In a transient mouse model, fingolimod reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size, neurological deficit, <z:hpo ids='HP_0000969'>edema</z:hpo>, and the number of dying cells in the core and periinfarct area </plain></SENT>
<SENT sid="5" pm="."><plain>Neuroprotection was accompanied by decreased <z:mp ids='MP_0001845'>inflammation</z:mp>, as fingolimod-treated mice had fewer activated neutrophils, microglia/macrophages, and intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1)-positive blood vessels </plain></SENT>
<SENT sid="6" pm="."><plain>Fingolimod-treated mice showed a smaller <z:mpath ids='MPATH_124'>infarct</z:mpath> and performed better in behavioral tests up to 15 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> was observed in a permanent model even when mice were treated 4 hours after ischemic <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Fingolimod also decreased <z:mpath ids='MPATH_124'>infarct</z:mpath> size in a rat model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Fingolimod did not protect primary neurons against <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> excitotoxicity or <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi>, but decreased ICAM-1 expression in brain endothelial cells stimulated by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha </plain></SENT>
<SENT sid="10" pm="."><plain>INTERPRETATION: These findings suggest that anti-inflammatory mechanisms, and possibly vasculoprotection, rather than direct effects on neurons, underlie the beneficial effects of fingolimod after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>S1P receptors are a highly promising target in <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
</text></document>